Business Description
Bioventus Inc
NAICS : 339112
SIC : 3845
4721 Emperor Boulevard, Suite 100, Durham, NC, USA, 27703
Description
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.07 | |||||
| Equity-to-Asset | 0.38 | |||||
| Debt-to-Equity | 0.82 | |||||
| Debt-to-EBITDA | 25.09 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0.85 | |||||
| Beneish M-Score | -2.02 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8 | |||||
| 3-Year EBITDA Growth Rate | -9.3 | |||||
| 3-Year EPS without NRI Growth Rate | 59.6 | |||||
| 3-Year FCF Growth Rate | -63.2 | |||||
| 3-Year Book Growth Rate | 43.4 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 14.64 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 68.96 | |||||
| 9-Day RSI | 64.26 | |||||
| 14-Day RSI | 59.85 | |||||
| 6-1 Month Momentum % | -37.32 | |||||
| 12-1 Month Momentum % | -49.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.43 | |||||
| Quick Ratio | 1.05 | |||||
| Cash Ratio | 0.16 | |||||
| Days Inventory | 117.14 | |||||
| Days Sales Outstanding | 84.7 | |||||
| Days Payable | 34.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.3 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 68.36 | |||||
| Operating Margin % | -4.62 | |||||
| Net Margin % | -3.61 | |||||
| ROE % | -6.26 | |||||
| ROA % | -1.93 | |||||
| ROIC % | -2.51 | |||||
| ROC (Joel Greenblatt) % | -38.67 | |||||
| ROCE % | -3.59 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 67.26 | |||||
| Forward PE Ratio | 14.64 | |||||
| PE Ratio without NRI | 67.26 | |||||
| Price-to-Owner-Earnings | 34.53 | |||||
| PEG Ratio | 3.19 | |||||
| PS Ratio | 0.96 | |||||
| PB Ratio | 1.24 | |||||
| Price-to-Free-Cash-Flow | 71.5 | |||||
| Price-to-Operating-Cash-Flow | 16.45 | |||||
| EV-to-EBIT | -35.34 | |||||
| EV-to-EBITDA | 61.37 | |||||
| EV-to-Revenue | 1.93 | |||||
| EV-to-Forward-Revenue | 1.63 | |||||
| EV-to-FCF | -228.4 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.32 | |||||
| Earnings Yield (Greenblatt) % | -2.83 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:BVS
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 466.41 | ||
| EPS (TTM) ($) | 0.135 | ||
| Beta | 0 | ||
| Volatility % | 55.13 | ||
| 14-Day RSI | 59.85 | ||
| 14-Day ATR ($) | 0.556644 | ||
| 20-Day SMA ($) | 8.296 | ||
| 12-1 Month Momentum % | -49.14 | ||
| 52-Week Range ($) | 6.3 - 17.53 | ||
| Shares Outstanding (Mil) | 61.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bioventus Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||